Warfarin: pharmacological profile and drug interactions with antidepressants

Teles, Juliana Souto; Fukuda, Ellen Yukie; Feder, David

doi:10.1590/s1679-45082012000100024

Cited by 34 publications

(34 citation statements)

References 19 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study on the pharmacological profile and drug interactions with antidepressants, the drugs most frequently reported included simvastatin and ciprofloxacin. It should be added that the indication of the use of anticoagulants, along with other medications, increased as a result of age, due to the aging process that causes comorbidities (11) .…”

Section: Discussionmentioning

confidence: 99%

Sociodemographic and clinical profile of patients treated with oral anticoagulants

Figueirêdo¹,

Araújo²,

Silva³

et al. 2018

Rev Rene

View full text Add to dashboard Cite

Objective: to describe the sociodemographic and clinical profile of patients treated with oral anticoagulants. Methods: cross-sectional study, conducted in an anticoagulation outpatient facility of a teaching hospital which is reference in cardiology. One evaluated 222 patients, through individual interviews using a structured questionnaire. Data were analyzed using descriptive statistics. Results: the participants were characterized predominantly by the following characteristics: female (64.4%); brown (57.2%); low education (68.0%); poor (67.1%); most with values of the International Normalized Ratio outside the therapeutic range (57.2%); associated comorbidities and prolonged treatment time (65.8%). Conclusion: it was evident a predominantly female group, with low socioeconomic status, associated comorbidities and prolonged treatment time with oral anticoagulants. It constitutes the biggest part of a vulnerable group whose characteristics can affect the quality of the treatment, and with characteristics related to the particular culture of northeastern Brazil, not found in anticoagulation outpatient facilities in other regions of the country. Descriptors: Cardiovascular Diseases; Anticoagulants; Health Profile.Objetivo: descrever o perfil sociodemográfico e clínico de pacientes em tratamento com anticoagulantes orais. Métodos: estudo transversal, desenvolvido em ambulatório de anticoagulação de um hospital de ensino e referência na área de Cardiologia. Foram avaliados 222 pacientes, por meio de entrevistas individuais, com questionário estruturado. Os dados foram analisados usando estatística descritiva. Resultados: os participantes caracterizaram-se predominantemente por: sexo feminino (64,4%); cor parda (57,2%); baixa escolaridade (68,0%); baixa renda (67,1%); maioria apresentando valores do International Normalized Ratio fora da faixa terapêutica (57,2%); comorbidades associadas; e tempo de tratamento prolongado (65,8%). Conclusão: evidenciou-se grupo predominantemente do sexo feminino, com baixo nível socioeconômico, comorbidades associadas e tempo de tratamento prolongado com anticoagulantes orais. Constitui-se, em maior parte, de um grupo vulnerável, cuja característica pode interferir na qualidade do tratamento, e com especificidades relacionadas à cultura particular da região Nordeste do Brasil, não encontradas em ambulatórios de anticoagulação de outras regiões do país.

show abstract

Section: Discussionmentioning

confidence: 99%

Sociodemographic and clinical profile of patients treated with oral anticoagulants

Figueirêdo¹,

Araújo²,

Silva³

et al. 2018

Rev Rene

View full text Add to dashboard Cite

show abstract

“…It is also used to treat patients following prosthetic heart valve replacement surgeries, recurrent myocardial infarction and also the treatment of transient ischemic attacks. The primary goal of warfarin treatment is to maintain the target international normalized ratio [3]. Complications of warfarin include nausea, diarrhea, vomiting, elevation of liver enzymes, renal nephropathy, skin necrosis, purple toe syndrome, bleeding complications, leukopenia, and agranulocytosis [4].…”

Section: Discussionmentioning

confidence: 99%

“…TE is strongly suspected as the mechanism due to timing and presentation of hair loss induced by warfarin. Another mechanism attributed to warfarin-induced hair loss includes change in vasculature of scalp leading to focal degeneration of the connective near the blood vessels of follicular connective tissue sheath [3,5]. It is also noted that when the hair follicles enter the telogen phase asynchronously following chronic exposure of drugs, the hair fall becomes clinically significant only after months or years of treatment with the offending drug.…”

Section: Discussionmentioning

confidence: 99%

Warfarin-Induced Alopecia: A Rare Case Report

Saurab

Ommurugan

Priya

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

As new drugs are developed everywhere worldwide to combat many diseases, side effects due to drugs are always a matter of concern. Warfarin is indicated for the treatment of venous thromboembolism over many decades and it is always associated with many side effects ranging from bleeding complications, gastrointestinal disturbances to skin necrosis. Hair fall with oral anticoagulants had always been a matter of debate and concern and so far, only very few case reports have been published on warfarin-induced hair loss. Hence, we report a case of warfarin-induced alopecia in a 39-yearold male in a tertiary care hospital in Southern India.

show abstract

“…Warfarin use in the period was included as anticoagulants are associated with stroke and warfarin is the most commonly prescribed anticoagulant in the US. 21,25,26 Length of hospital stay and discharge to a SNF were included as covariates as they may be indicative of TBI severity. 21 …”

Section: Methodsmentioning

confidence: 99%

Risk of Stroke Among Older Medicare Antidepressant Users With Traumatic Brain Injury

Khokhar¹,

Simoni

Albrecht³

2017

Journal of Head Trauma Rehabilitation

View full text Add to dashboard Cite

Objective To estimate the risk of stroke associated with new antidepressant use among older adults with traumatic brain injury (TBI). Participants 64,214 Medicare beneficiaries aged ≥65 years meeting inclusion criteria and hospitalized with a TBI during 2006 to 2010. Design New user design. Generalized estimating equations were used to estimate the relative risks (RR) of stroke. Main Measures Primary exposure was new antidepressant use following TBI identified through Medicare Part D claims. The primary outcome was stroke following TBI. Ischemic and hemorrhagic stroke were secondary outcomes. Results 20,859 (32%) beneficiaries used an antidepressant at least once following TBI. Selective serotonin reuptake inhibitors (SSRIs) accounted for the majority of antidepressant use. SSRI use was associated with an increased risk of hemorrhagic stroke (relative risk (RR)= 1.26; 95% confidence interval (CI)= 1.06, 1.50), but not ischemic stroke (RR=1.04; 95% CI= 0.94, 1.15). The SSRIs escitalopram (RR 1.33, 95% CI: 1.02, 1.74) and sertraline (RR=1.46; 95% CI= 1.10, 1.94) were associated with an increase in the risk of hemorrhagic stroke. Conclusion Findings from this study will aid prescribers in choosing appropriate antidepressants to treat depression in older adults with TBI.

show abstract

Warfarin: pharmacological profile and drug interactions with antidepressants

Cited by 34 publications

References 19 publications

Sociodemographic and clinical profile of patients treated with oral anticoagulants

Sociodemographic and clinical profile of patients treated with oral anticoagulants

Warfarin-Induced Alopecia: A Rare Case Report

Risk of Stroke Among Older Medicare Antidepressant Users With Traumatic Brain Injury

Contact Info

Product

Resources

About